← All trials
NCT05144984
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 29, 2021
- Primary completion
- Oct 26, 2022
- Completion date
- Jan 30, 2023
- First posted
- Dec 6, 2021
- Last posted
- Dec 6, 2021
- Enrollment
- 495
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.